Pharmacological Characterization of 40 Human Melanocortin-4 Receptor Polymorphisms with the Endogenous Proopiomelanocortin-Derived Agonists and the Agouti-Related Protein (AGRP) Antagonist,
- 19 May 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 45 (23) , 7277-7288
- https://doi.org/10.1021/bi0600300
Abstract
The melanocortin-4 receptor (MC4R) is a G-protein coupled receptor (GPCR) that is expressed in the central nervous system and has a role in regulating energy homeostasis and obesity. Up to a remarkable 6% of morbidly obese adults and children studied possess single nucleotide polymorphisms (SNPs) of the MC4R. Upon stimulation by agonist, the MC4R signals through the intracellular adenylate cyclase signal transduction pathway. Posttranslational modification of the pro-opiomelanocortin (POMC) gene transcript results in the generation of several endogenous melanocortin receptor agonists including α-, β-, γ-melanocyte stimulating hormones (MSH) and adrenocorticotropin (ACTH) ligands. The endogenous MC4R antagonist, agouti-related protein (AGRP), is expressed in the brain and is only one of two naturally occurring antagonists of GPCRs identified to date. Herein, we have generated 40 hMC4 polymorphic receptors and evaluated their cell surface expression by flow cytometry as well as pharmacologically characterized their functionality using the endogenous agonists α-MSH, β-MSH, γ2-MSH, ACTH(1−24), the antagonist hAGRP(87−132), and the synthetic agonists NDP-MSH and MTII. This is the first study in which polymorphic hMC4Rs have been pharmacologically characterized simultaneously with multiple endogenous ligands. Interestingly, at the N97D, L106P, and C271Y hMC4Rs β-MSH was more potent than the other endogenous agonists α-MSH, γ2-MSH, ACTH(1−24). The S58C and R165Q/W hMC4Rs possessed significantly reduced endogenous agonist potency (15- to 90-fold), but the synthetic ligands NDP-MSH and MTII possessed only 2−9-fold reduced potency as compared to the wild-type receptor, suggesting their potential as therapeutic ligands to treat individuals with these polymorphisms.Keywords
This publication has 27 references indexed in Scilit:
- Poor Cell Surface Expression of Human Melanocortin-4 Receptor Mutations Associated with ObesityJournal of Biological Chemistry, 2003
- Cell Surface Expression of the Melanocortin-4 Receptor Is Dependent on a C-terminal Di-isoleucine Sequence at Codons 316/317Journal of Biological Chemistry, 2003
- A novel nonsense mutation in the melanocortin-4 receptor associated with obesity in a Spanish populationInternational Journal of Obesity, 2003
- Expression of melanocortin 4 receptor mRNA in the central nervous system of the ratJournal of Comparative Neurology, 2003
- Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesityJournal of Endocrinology, 2002
- Structure Activity Studies of the Melanocortin-4 Receptor by in Vitro Mutagenesis: Identification of Agouti-Related Protein (AGRP), Melanocortin Agonist and Synthetic Peptide Antagonist Interaction DeterminantsBiochemistry, 2001
- Phenotypes in Three Pedigrees with Autosomal Dominant Obesity Caused by Haploinsufficiency Mutations in the Melanocortin-4 Receptor GeneAmerican Journal of Human Genetics, 1999
- Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitusJournal of Clinical Investigation, 1999
- Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNAFEBS Letters, 1992
- Structure and Biosynthesis of Pro-Adrenocorticotropin/Endorphin and Related Peptides*Endocrine Reviews, 1980